Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes

Galectin-3 (Gal-3) has been associated with heart failure (HF) and poor cardiovascular outcomes. However, the effect of longitudinal changes in Gal-3 on clinical outcomes remains unclear. The authors sought to study clinical determinants of change in Gal-3 among community-dwelling individuals. Furth...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of the American College of Cardiology Jg. 72; H. 25; S. 3246
Hauptverfasser:	Ghorbani, Anahita, Bhambhani, Vijeta, Christenson, Robert H, Meijers, Wouter C, de Boer, Rudolf A, Levy, Daniel, Larson, Martin G, Ho, Jennifer E
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 25.12.2018
Schlagworte:	Aged Biomarkers - blood Blood Proteins Cardiovascular Diseases - blood Cardiovascular Diseases - diagnosis Cardiovascular Diseases - mortality Cohort Studies Female Galectin 3 - blood Galectins Humans Incidence Longitudinal Studies Male Middle Aged Mortality - trends Prospective Studies mortality cardiovascular disease heart failure biomarker change in galectin-3 galectin-3
ISSN:	1558-3597, 1558-3597
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Abstract	Galectin-3 (Gal-3) has been associated with heart failure (HF) and poor cardiovascular outcomes. However, the effect of longitudinal changes in Gal-3 on clinical outcomes remains unclear. The authors sought to study clinical determinants of change in Gal-3 among community-dwelling individuals. Further, they sought to examine the role of serial Gal-3 measurements in predicting risk of future HF, cardiovascular disease (CVD), and mortality. A total of 2,477 participants in the Framingham Heart Study Offspring cohort underwent measurement of plasma Gal-3 levels at 2 examinations (1995 to 1998 and 2005 to 2008). Linear regression models were used to examine clinical correlates of change in Gal-3. Proportional hazards models were used to relate future clinical outcomes with change in Gal-3. The following clinical correlates were associated with greater longitudinal increases in Gal-3 levels: age, female sex, hypertension, diabetes, body mass index, interim development of chronic kidney disease, and HF (p < 0.0001 for all in multivariable model). Change in Gal-3 was associated with future HF (hazard ratio [HR]: 1.39 per 1-SD increase; 95% confidence interval [CI]: 1.13 to 1.71), CVD (HR: 1.29; 95% CI: 1.11 to 1.51), and all-cause mortality (HR: 1.30; 95% CI: 1.17 to 1.46). Change in Gal-3 was associated with both HF with preserved as well as reduced ejection fraction (p < 0.05 for both). Longitudinal changes in Gal-3 are associated with traditional cardiovascular risk factors and renal disease. In turn, change in Gal-3 predicts future HF, CVD, and mortality in the community. Future studies are needed to determine whether serial Gal-3 measures may be useful in disease prevention.
AbstractList	Galectin-3 (Gal-3) has been associated with heart failure (HF) and poor cardiovascular outcomes. However, the effect of longitudinal changes in Gal-3 on clinical outcomes remains unclear. The authors sought to study clinical determinants of change in Gal-3 among community-dwelling individuals. Further, they sought to examine the role of serial Gal-3 measurements in predicting risk of future HF, cardiovascular disease (CVD), and mortality. A total of 2,477 participants in the Framingham Heart Study Offspring cohort underwent measurement of plasma Gal-3 levels at 2 examinations (1995 to 1998 and 2005 to 2008). Linear regression models were used to examine clinical correlates of change in Gal-3. Proportional hazards models were used to relate future clinical outcomes with change in Gal-3. The following clinical correlates were associated with greater longitudinal increases in Gal-3 levels: age, female sex, hypertension, diabetes, body mass index, interim development of chronic kidney disease, and HF (p < 0.0001 for all in multivariable model). Change in Gal-3 was associated with future HF (hazard ratio [HR]: 1.39 per 1-SD increase; 95% confidence interval [CI]: 1.13 to 1.71), CVD (HR: 1.29; 95% CI: 1.11 to 1.51), and all-cause mortality (HR: 1.30; 95% CI: 1.17 to 1.46). Change in Gal-3 was associated with both HF with preserved as well as reduced ejection fraction (p < 0.05 for both). Longitudinal changes in Gal-3 are associated with traditional cardiovascular risk factors and renal disease. In turn, change in Gal-3 predicts future HF, CVD, and mortality in the community. Future studies are needed to determine whether serial Gal-3 measures may be useful in disease prevention. Galectin-3 (Gal-3) has been associated with heart failure (HF) and poor cardiovascular outcomes. However, the effect of longitudinal changes in Gal-3 on clinical outcomes remains unclear.BACKGROUNDGalectin-3 (Gal-3) has been associated with heart failure (HF) and poor cardiovascular outcomes. However, the effect of longitudinal changes in Gal-3 on clinical outcomes remains unclear.The authors sought to study clinical determinants of change in Gal-3 among community-dwelling individuals. Further, they sought to examine the role of serial Gal-3 measurements in predicting risk of future HF, cardiovascular disease (CVD), and mortality.OBJECTIVESThe authors sought to study clinical determinants of change in Gal-3 among community-dwelling individuals. Further, they sought to examine the role of serial Gal-3 measurements in predicting risk of future HF, cardiovascular disease (CVD), and mortality.A total of 2,477 participants in the Framingham Heart Study Offspring cohort underwent measurement of plasma Gal-3 levels at 2 examinations (1995 to 1998 and 2005 to 2008). Linear regression models were used to examine clinical correlates of change in Gal-3. Proportional hazards models were used to relate future clinical outcomes with change in Gal-3.METHODSA total of 2,477 participants in the Framingham Heart Study Offspring cohort underwent measurement of plasma Gal-3 levels at 2 examinations (1995 to 1998 and 2005 to 2008). Linear regression models were used to examine clinical correlates of change in Gal-3. Proportional hazards models were used to relate future clinical outcomes with change in Gal-3.The following clinical correlates were associated with greater longitudinal increases in Gal-3 levels: age, female sex, hypertension, diabetes, body mass index, interim development of chronic kidney disease, and HF (p < 0.0001 for all in multivariable model). Change in Gal-3 was associated with future HF (hazard ratio [HR]: 1.39 per 1-SD increase; 95% confidence interval [CI]: 1.13 to 1.71), CVD (HR: 1.29; 95% CI: 1.11 to 1.51), and all-cause mortality (HR: 1.30; 95% CI: 1.17 to 1.46). Change in Gal-3 was associated with both HF with preserved as well as reduced ejection fraction (p < 0.05 for both).RESULTSThe following clinical correlates were associated with greater longitudinal increases in Gal-3 levels: age, female sex, hypertension, diabetes, body mass index, interim development of chronic kidney disease, and HF (p < 0.0001 for all in multivariable model). Change in Gal-3 was associated with future HF (hazard ratio [HR]: 1.39 per 1-SD increase; 95% confidence interval [CI]: 1.13 to 1.71), CVD (HR: 1.29; 95% CI: 1.11 to 1.51), and all-cause mortality (HR: 1.30; 95% CI: 1.17 to 1.46). Change in Gal-3 was associated with both HF with preserved as well as reduced ejection fraction (p < 0.05 for both).Longitudinal changes in Gal-3 are associated with traditional cardiovascular risk factors and renal disease. In turn, change in Gal-3 predicts future HF, CVD, and mortality in the community. Future studies are needed to determine whether serial Gal-3 measures may be useful in disease prevention.CONCLUSIONSLongitudinal changes in Gal-3 are associated with traditional cardiovascular risk factors and renal disease. In turn, change in Gal-3 predicts future HF, CVD, and mortality in the community. Future studies are needed to determine whether serial Gal-3 measures may be useful in disease prevention.
Author	Bhambhani, Vijeta Christenson, Robert H Levy, Daniel Larson, Martin G Ho, Jennifer E Meijers, Wouter C Ghorbani, Anahita de Boer, Rudolf A
Author_xml	– sequence: 1 givenname: Anahita surname: Ghorbani fullname: Ghorbani, Anahita organization: Calhoun Cardiology Center, University of Connecticut Health Center, Farmington, Connecticut – sequence: 2 givenname: Vijeta surname: Bhambhani fullname: Bhambhani, Vijeta organization: Cardiovascular Research Center, Massachusetts General Hospital, Boston, Massachusetts; Cardiology Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts – sequence: 3 givenname: Robert H surname: Christenson fullname: Christenson, Robert H organization: Department of Pathology, University of Maryland School of Medicine, Baltimore, Maryland – sequence: 4 givenname: Wouter C surname: Meijers fullname: Meijers, Wouter C organization: Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands – sequence: 5 givenname: Rudolf A surname: de Boer fullname: de Boer, Rudolf A organization: Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands – sequence: 6 givenname: Daniel surname: Levy fullname: Levy, Daniel organization: National Heart, Lung, and Blood Institute, Boston University's Framingham Heart Study, Framingham, Massachusetts; Population Sciences Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland – sequence: 7 givenname: Martin G surname: Larson fullname: Larson, Martin G organization: Framingham Heart Study, Framingham, Massachusetts; Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts – sequence: 8 givenname: Jennifer E surname: Ho fullname: Ho, Jennifer E email: jho1@mgh.harvard.edu organization: Cardiovascular Research Center, Massachusetts General Hospital, Boston, Massachusetts; Cardiology Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: jho1@mgh.harvard.edu
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/30573026$$D View this record in MEDLINE/PubMed
BookMark	eNpNj81Kw0AYRQep2B99ARcySzeJ85OZzCwl2FoodKPr8GXypU5JJjWTCL69Qiu4OndxuHCWZBb6gITcc5ZyxvXTMT2Cc6lg3KTMpizXV2TBlTKJVDaf_dtzsozxyBjThtsbMpdM5ZIJvSDrXR8OfpxqH6ClxQeEA1If6AZadKMPiaQQaroNztcYRlrAUPv-C6KbWhjofhpd32G8JdcNtBHvLlyR9_XLW_Ga7PabbfG8S5xWakykNCiNQuUwgzyrjW64sFojk42wmai048BBZxaZaiqpHLC8YpWsFK-MkGJFHs-_p6H_nDCOZeejw7aFgP0US8GVtSbLhP1VHy7qVHVYl6fBdzB8l3_t4gfsMl0W
CitedBy_id	crossref_primary_10_1161_JAHA_123_031607 crossref_primary_10_3390_biom13010173 crossref_primary_10_3389_fcvm_2022_818162 crossref_primary_10_3389_fcvm_2021_706490 crossref_primary_10_1155_ijvm_7431078 crossref_primary_10_1016_j_mayocp_2022_10_013 crossref_primary_10_1111_ctr_14592 crossref_primary_10_3390_ijms23105680 crossref_primary_10_1016_j_ijcard_2024_132723 crossref_primary_10_1007_s00380_022_02222_9 crossref_primary_10_3389_fcvm_2021_829151 crossref_primary_10_1056_NEJMra1916393 crossref_primary_10_3390_jcdd8110139 crossref_primary_10_1007_s11906_021_01135_8 crossref_primary_10_1002_smll_202305940 crossref_primary_10_1016_j_cardfail_2025_02_014 crossref_primary_10_1161_JAHA_121_023238 crossref_primary_10_1016_j_jacc_2019_01_045 crossref_primary_10_3390_ijms241713111 crossref_primary_10_1002_ehf2_13174 crossref_primary_10_1371_journal_pone_0298284 crossref_primary_10_1016_j_cca_2020_07_040 crossref_primary_10_1093_eurheartj_ehac128 crossref_primary_10_3390_ijms22062955 crossref_primary_10_1007_s00246_025_03935_0 crossref_primary_10_1161_JAHA_119_015405 crossref_primary_10_1016_j_diabres_2020_108082 crossref_primary_10_1016_j_xkme_2025_101089 crossref_primary_10_1002_ehf2_12612 crossref_primary_10_1111_bph_14674 crossref_primary_10_1055_s_0040_1721144 crossref_primary_10_1186_s12889_024_18811_4 crossref_primary_10_1016_j_jacc_2018_09_077 crossref_primary_10_1016_j_clnu_2025_03_001 crossref_primary_10_1002_ejhf_1771 crossref_primary_10_1158_0008_5472_CAN_20_2799 crossref_primary_10_1161_CIRCRESAHA_121_319916 crossref_primary_10_1016_j_jaccao_2023_03_015 crossref_primary_10_2217_bmm_2018_0488 crossref_primary_10_3390_jcm14103345 crossref_primary_10_1007_s11255_019_02123_3 crossref_primary_10_3390_cimb47050332 crossref_primary_10_3389_fcvm_2023_1175174 crossref_primary_10_1016_j_numecd_2022_03_001 crossref_primary_10_1155_2019_9529053 crossref_primary_10_1007_s40256_019_00387_9 crossref_primary_10_1016_j_jacc_2019_02_016 crossref_primary_10_1093_eurheartj_ehac034 crossref_primary_10_1002_ehf2_13118 crossref_primary_10_1253_circj_CJ_25_0002 crossref_primary_10_3390_ijms21239232 crossref_primary_10_1007_s40200_022_01044_w crossref_primary_10_1007_s11897_024_00686_6 crossref_primary_10_1016_j_scib_2024_03_042 crossref_primary_10_3390_biom10030389 crossref_primary_10_3389_fphys_2023_1090724
ContentType	Journal Article
Copyright	Copyright © 2018 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Copyright_xml	– notice: Copyright © 2018 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1016/j.jacc.2018.09.076
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine
EISSN	1558-3597
ExternalDocumentID	30573026
Genre	Journal Article Observational Study Research Support, N.I.H., Extramural
GrantInformation_xml	– fundername: NHLBI NIH HHS grantid: R01 HL134893 – fundername: NHLBI NIH HHS grantid: HHSN268201500001I – fundername: NHLBI NIH HHS grantid: K23 HL116780 – fundername: NHLBI NIH HHS grantid: N01 HC025195 – fundername: NHLBI NIH HHS grantid: R01 HL140224 – fundername: NHLBI NIH HHS grantid: HHSN268201500001C
GroupedDBID	--- --K --M .1- .FO .~1 0R~ 18M 1B1 1P~ 1~. 1~5 2WC 4.4 457 4G. 53G 5GY 5RE 5VS 6PF 7-5 71M 8P~ AABNK AABVL AAEDT AAEDW AAIKJ AAKUH AALRI AAOAW AAQFI AAQQT AAXUO ABBQC ABFNM ABFRF ABLJU ABMAC ABMZM ABOCM ACGFO ACGFS ACIUM ACJTP ACPRK ACVFH ADBBV ADCNI ADEZE ADVLN AEFWE AEKER AENEX AEUPX AEVXI AEXQZ AFCTW AFETI AFPUW AFRAH AFRHN AFTJW AGCQF AGYEJ AHMBA AIGII AITUG AJRQY AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ BAWUL BLXMC CGR CS3 CUY CVF DIK DU5 E3Z EBS ECM EFKBS EIF EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FNPLU G-Q GBLVA GX1 H13 HVGLF IHE IXB J1W K-O KQ8 L7B MO0 N9A NPM O-L O9- OA. OAUVE OK1 OL~ OZT P-8 P-9 P2P PC. PQQKQ Q38 RIG ROL RPZ SCC SDF SDG SDP SES SSZ TR2 UNMZH UV1 W8F WH7 WOQ WOW YYM YZZ Z5R 7X8 EFLBG ~HD
ID	FETCH-LOGICAL-c655t-338e385e5ce4a74d86f12966e03f2942b6c1a1a649e05fb35ca07b0b3b51b8232
IEDL.DBID	7X8
ISICitedReferencesCount	62
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000453380000003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1558-3597
IngestDate	Sun Nov 09 14:04:27 EST 2025 Mon Jul 21 05:35:37 EDT 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	25
Keywords	mortality cardiovascular disease heart failure biomarker change in galectin-3 galectin-3
Language	English
License	Copyright © 2018 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c655t-338e385e5ce4a74d86f12966e03f2942b6c1a1a649e05fb35ca07b0b3b51b8232
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3
OpenAccessLink	https://www.clinicalkey.com/#!/content/1-s2.0-S073510971838906X
PMID	30573026
PQID	2159984429
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_2159984429 pubmed_primary_30573026
PublicationCentury	2000
PublicationDate	2018-12-25
PublicationDateYYYYMMDD	2018-12-25
PublicationDate_xml	– month: 12 year: 2018 text: 2018-12-25 day: 25
PublicationDecade	2010
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	Journal of the American College of Cardiology
PublicationTitleAlternate	J Am Coll Cardiol
PublicationYear	2018
References	30573027 - J Am Coll Cardiol. 2018 Dec 25;72(25):3255-3258. doi: 10.1016/j.jacc.2018.09.077. 30975312 - J Am Coll Cardiol. 2019 Apr 16;73(14):1875-1876. doi: 10.1016/j.jacc.2019.02.016. 30975311 - J Am Coll Cardiol. 2019 Apr 16;73(14):1875. doi: 10.1016/j.jacc.2019.01.045.
References_xml	– reference: 30975311 - J Am Coll Cardiol. 2019 Apr 16;73(14):1875. doi: 10.1016/j.jacc.2019.01.045. – reference: 30573027 - J Am Coll Cardiol. 2018 Dec 25;72(25):3255-3258. doi: 10.1016/j.jacc.2018.09.077. – reference: 30975312 - J Am Coll Cardiol. 2019 Apr 16;73(14):1875-1876. doi: 10.1016/j.jacc.2019.02.016.
SSID	ssj0006819
Score	2.514857
Snippet	Galectin-3 (Gal-3) has been associated with heart failure (HF) and poor cardiovascular outcomes. However, the effect of longitudinal changes in Gal-3 on...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	3246
SubjectTerms	Aged Biomarkers - blood Blood Proteins Cardiovascular Diseases - blood Cardiovascular Diseases - diagnosis Cardiovascular Diseases - mortality Cohort Studies Female Galectin 3 - blood Galectins Humans Incidence Longitudinal Studies Male Middle Aged Mortality - trends Prospective Studies
Title	Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes
URI	https://www.ncbi.nlm.nih.gov/pubmed/30573026 https://www.proquest.com/docview/2159984429
Volume	72
WOSCitedRecordID	wos000453380000003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV07T8MwED4BRYiF96O8ZCRWiyR-xJkQqigMbekAqFvlOLZUhqSQlN_POUlVMSAhsWSzZJ2du-8e_j6AmyAzjAcupELHnGLEt1SzyFGjtFQiC1Jbc-m9DeLRSE0mybgtuJXtWOXSJ9aOOiuMr5HfYmjCzICj-7ybf1CvGuW7q62Exjp0GEIZP9IVT1Zs4VLVwh4YMhVliJzbRzPNfNe7Np7CMFQ1z2ksf4eYdajp7_53k3uw04JMct_cin1Ys_kBbA3bNvoh9AeFlylaZF4SizQPDMgsJ4_aF_FnOWVE5xlB3-ElRyvS-zG0Sp4XFW7Hlkfw2n946T3RVlCBGilERTEdtUwJK4zleDSZkg7DvZQ2YC5KeJRKE-pQS57YQLiUCaODOA1SloowVYi9jmEjL3J7CsQgstCKuwgXIQbzQN1FNs4EIgJuw6QL10sLTfHC-i6Ezm2xKKcrG3XhpDHzdN4wa0yZp2fErPDsD6vPYdufnh8ticQFdBz-rvYSNs1XNSs_r-qbgN_RePgNXIa7lQ
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Longitudinal+Change+in+Galectin-3+and+Incident+Cardiovascular+Outcomes&rft.jtitle=Journal+of+the+American+College+of+Cardiology&rft.au=Ghorbani%2C+Anahita&rft.au=Bhambhani%2C+Vijeta&rft.au=Christenson%2C+Robert+H&rft.au=Meijers%2C+Wouter+C&rft.date=2018-12-25&rft.issn=1558-3597&rft.eissn=1558-3597&rft.volume=72&rft.issue=25&rft.spage=3246&rft_id=info:doi/10.1016%2Fj.jacc.2018.09.076&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1558-3597&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1558-3597&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1558-3597&client=summon